Company intelligence / Profile preview

Beijing Weixiao Biotechnology

Beijing, Beijing, Chinaen.eaal.net ↗

Ownership: Private
Development stage: Other

Overview

The core product (EAL® cell therapy) completed Phase II enrollment (over 400 patients for solid tumor/liver cancer, with NDA submission expected in late 2024). CAR-T-19 for B-ALL and other gene-modified cell therapies are in clinical trials. A trial for 6B11-OCIK in ovarian cancer is suspended

Therapeutic areas: OncologyHematologyInfectious Diseases
Modalities: Cell therapyCAR-T cell therapyTCR-T cell therapyNon-genetically-modified cell therapyGenetically-modified cell therapy
Industry: Biotech

Drug pipeline

2 assets

EAL

NDA

Indications: Solid tumors

1 more asset in the full pipeline.

Request access →

Partnerships

Parent group is engaged in wide collaboration; subsidiary not shown to have unique partnerships

Beyond the preview

Go deeper on Beijing Weixiao Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Weixiao Biotechnology.

Explore the full profile